| __timestamp | Dynavax Technologies Corporation | Summit Therapeutics Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 6795238 |
| Thursday, January 1, 2015 | 22180000 | 7454247 |
| Friday, January 1, 2016 | 37257000 | 10345862 |
| Sunday, January 1, 2017 | 27367000 | 16984203 |
| Monday, January 1, 2018 | 64770000 | 16187290 |
| Tuesday, January 1, 2019 | 74986000 | 9299233.54 |
| Wednesday, January 1, 2020 | 79256000 | 19232000 |
| Friday, January 1, 2021 | 100156000 | 23611000 |
| Saturday, January 1, 2022 | 131408000 | 26700000 |
| Sunday, January 1, 2023 | 152946000 | 28215000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing operational costs is crucial for success. Over the past decade, Dynavax Technologies Corporation and Summit Therapeutics Inc. have showcased contrasting strategies in their Selling, General, and Administrative (SG&A) expenses.
From 2014 to 2023, Dynavax's SG&A expenses surged by over 760%, reflecting its aggressive expansion and investment in operational infrastructure. By 2023, their expenses reached a peak, indicating a robust growth strategy.
Conversely, Summit Therapeutics maintained a more conservative approach, with a 315% increase in SG&A expenses over the same period. This strategy highlights their focus on sustainable growth and cost efficiency.
These trends underscore the diverse strategies within the biotech sector, where companies balance between aggressive expansion and cautious growth to achieve long-term success.
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Summit Therapeutics Inc.
Breaking Down SG&A Expenses: Pfizer Inc. vs Dynavax Technologies Corporation
Selling, General, and Administrative Costs: United Therapeutics Corporation vs Summit Therapeutics Inc.
Neurocrine Biosciences, Inc. and Summit Therapeutics Inc.: SG&A Spending Patterns Compared
Intra-Cellular Therapies, Inc. vs Summit Therapeutics Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Summit Therapeutics Inc. vs Merus N.V. Trends and Insights
Summit Therapeutics Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Catalent, Inc. or Dynavax Technologies Corporation
Selling, General, and Administrative Costs: Ascendis Pharma A/S vs Dynavax Technologies Corporation
Selling, General, and Administrative Costs: Rhythm Pharmaceuticals, Inc. vs Dynavax Technologies Corporation
Cost Management Insights: SG&A Expenses for Dynavax Technologies Corporation and Galapagos NV
SG&A Efficiency Analysis: Comparing Dynavax Technologies Corporation and Novavax, Inc.